Skip to main content

Table 1 Demographic and clinical characteristics of each group

From: Lithium and preventing chemotherapy-induced peripheral neuropathy in breast cancer patients: a placebo-controlled randomized clinical trial

Variable Drug
N (%)
Placebo
N (%)
P value
Menopausal statement    0.735
 Pre-menopause 8 (44.4) 7 (38.9)  
 Menopause 10 (55.6) 11 (61.1)  
Stage of disease    0.728 
 1 1 (5.6) 1 (5.6)  
 2 10 (55.6) 11 (61.1)  
 3 7 (38.9) 6 (33.3)  
Affected lymph nodes   
 0 4 (22.2) 4 (22.2)  
 ≥1 14 (77.8) 14 (77.8)  
Tumor size (cm)    0.566 
 < 2 5 (27.8) 6 (33.3)  
 ≥ 2–5 10 (55.6) 11 (61.1)  
 ≥ 5 3 (16.7) 1 (5.6)  
Hormone therapy    0.682 
 Not received 3 (16.7) 3 (16.7)  
 Tamoxifen 3 (16.7) 2 (11.1)  
 Letrozol 6 (33.3) 5 (27.8)  
 Tamoxifen and letrozol 0 (0) 2 (11.1)  
 Tamoxifen and Decapeptyl 6 (3.3) 6 (33.3)  
Frequency of Taxol/Taxotere injection   
 4 17 (94.4) 17 (94.4)  
 > 4 1 (5.6) 1 (5.6)